by Madaline Spencer | Feb 15, 2025
Danya Kaye, UCB Pharma, discusses a study observing the profound burden of prolonged seizures in patients with epilepsy. The objective of this study was to explore the experiences of people with epilepsy living with prolonged seizures and their...
by Madaline Spencer | Feb 14, 2025
Carsten Utoft Niemann, MD, PhD, Copenhagen University Hospital, discusses results from the GLOW clinical trial in chronic lymphocytic leukemia (CLL). CLL is a rare cancer of the lymphocytes. Early signs and symptoms may include swollen lymph nodes,...
by Madaline Spencer | Feb 13, 2025
Deeksha Vishwamitra, Janssen Research & Development, discusses an analysis of the TRIMM-2 clinical trial evaluating combination therapy tal-DP in patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm...
by Madaline Spencer | Feb 12, 2025
The U.S. Food and Drug Administration has approved Gomekli (mirdametinib) for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas. Neurofibromatosis type 1 (NF1) is a genetic condition that affects the skin,...
by Madaline Spencer | Feb 12, 2025
Anita D’Souza, MD, Medical College of Wisconsin, discusses results from the MajesTEC-2 and TRIMM-2 clinical trials for combination therapy teclistamab + daratumumab + pomalidomide (tec-DP) in patients with multiple myeloma. Multiple myeloma is a bone...
